Singapore markets closed

Straits Times Index
3,410.81
-29.07(-0.85%)
Nikkei
40,912.37
-1.28(-0.00%)
Hang Seng
17,799.61
-228.67(-1.27%)
FTSE 100
8,203.93
-37.33(-0.45%)
Bitcoin USD
56,534.98
+2,435.98(+4.50%)
CMC Crypto 200
1,176.50
-32.19(-2.66%)

PTCT Aug 2024 35.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

1.2200

-2.4900

(-67.12%)

At close: 03:47PM EDT

Loading interactive chart…

Zacks
PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug
PTC Therapeutics (PTCT) falls as the EC's advisory committee adopts a negative opinion regarding the renewal of the conditional marketing approval of Translarna to treat nmDMD in the EU.
PR Newswire
CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the CHMP has issued a negative opinion on the renewal of the conditional marketing authorization of Translarna™ (ataluren) for the treatment of nmDMD. This opinion follows the return of the previously issued negative opinion by the European Commission (EC) for re-review.
Zacks
PTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock?
PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.